Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1

Conditions

Pancreatic Neoplasms 8Unspecified Adult Solid Tumor, Protocol Specific 1Resectable Pancreatic Carcinoma 1Resectable Pancreatic Cancer 1Rectal Neoplasms 1Prostatic Neoplasms 1Pancreatic Ductal Adenocarcinoma 1Neoplasms, Plasma Cell 1Neoplasm Metastasis 1Myelodysplastic Syndromes 1Multiple Myeloma 1Leukemia, Myelomonocytic, Chronic 1Leukemia 1Breast Neoplasms 1Anemia, Refractory, with Excess of Blasts 1Anemia, Refractory 1Adenocarcinoma of the Pancreas 1Adenocarcinoma 1

Interventions

Dexamethasone 420Lenalidomide 265Cyclophosphamide 246Bortezomib 241Melphalan 191Calcium Dobesilate 165fludarabine phosphate 112daratumumab 103Peripheral Blood Stem Cell Transplantation 99carfilzomib 92Thalidomide 90Filgrastim 88Mycophenolic Acid 82fludarabine 81pomalidomide 80Whole-Body Irradiation 80Busulfan 74Tacrolimus 71Granulocyte Colony-Stimulating Factor 66Cyclosporine 58dexamethasone acetate 56ixazomib 55Antilymphocyte Serum 50dexamethasone 21-phosphate 49auricularum 44Etoposide 39isatuximab 38Radiotherapy 36Stem Cell Transplantation 34Methotrexate 33

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Multiple Myeloma × paricalcitol × Clear all
NCT00258258 2013-02-01

Paricalcitol and Zoledronate in Treating Patients With Relapsed or Refractory Multiple Myeloma or Other Plasma Cell Disorders

Roswell Park Cancer Institute

Phase 1 Terminated
7 enrolled
Plasma cell

Multiple Myeloma, Neoplasms, Plasma Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡